Fig. 1
From: The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer
The promoter of EphA7 is significantly hypermethylated in CC tissues. a EphA7 hypermethylation was observed in 15 out of 23 categories of cancer tissues compared with adjacent normal tissues (P < 0.05) based on the UALCAN web tool, and the median beta value of CESC was the most prominent (△beta value = 0.464, P < 0.05). BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; TGCT: Testicular germ cell tumors; STAD: Stomach adenocarcinoma; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine corpus endometrial carcinoma. b There was no significant difference in EphA7 methylation between SCC and ADC. c The levels of mean EphA7 methylation at a total of 21 probes sites. Among them, all the 11 probes in the promoter region (blue) exhibited significant differences between tumor and adjacent normal specimens (P < 0.05). * represents adjusted P value < 0.05. Plot and P value were produced via Wanderer. d Pyrosequencing showed that EphA7 promoter methylation was higher in the tumor tissues compared with normal. e Compared with the normal cervical tissues (n = 5), the average promoter methylation level of EphA7 within a total of 11 CpG sites was 4.09-fold higher in tumors (n = 5) according to pyrosequencing